Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | -1.10% | +0.56% | -39.82% |
Jun. 05 | Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis | CI |
Jun. 03 | Lucien Selce Sends Letter to Aurinia shareholders | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.82% | 779M | |
+18.80% | 125B | |
+15.42% | 109B | |
-1.33% | 24.74B | |
+2.88% | 22.67B | |
-9.86% | 18.14B | |
-41.04% | 16.67B | |
-11.90% | 16.64B | |
+0.73% | 13.45B | |
+23.23% | 11.32B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M